Mumbai, Oct. 23 -- The company confirmed that its product is bioequivalent and therapeutically equivalent to the reference drug, Naropin Injection, marketed by Fresenius Kabi USA, LLC (NDA - 020533). Glenmark plans to commence distribution of the injection from November 2025.

According to IQVIA sales data for the 12-month period ending August 2025, the Naropin Injection market recorded annual sales of approximately $20.9 million in the US.

Commenting on the launch, Marc Kikuchi, president & business head, North America said, "We are pleased to announce the launch of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. This launch represents another importan...